UPDATE: The FDA has made a new decision July 31, 2021 on the use of REGENERON-COV in that some of us who are considered vulnerable to SARS-CoV-2 virus may now qualify for the antibodies under certain conditions. This certainly is a move in the right direction. The information is contained in this link: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-30-2021 The … Continue reading Navigating the Covid-19 Vaccine Debates and Concerns of Efficacy for Blood Cancer Patients in the United States